Inovio Pharma (INO) Reports Q1 Loss of $0.30/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results
May 9, 2019 4:05 PM EDTPLYMOUTH MEETING, Pa., May 9, 2019 /PRNewswire/ --Â Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic nucleic technology targeted against cancers and infectious diseases, today reported financial results for the first quarter ended March 31, 2019. Inovio's management will host a live conference call and webcast at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update.
Inovio Highlights
VGX-3100/INO-3106; HPV-related Pre-cancersInovio's Phase 3 trials for VGX-3100, REVEAL 1 and REVEAL... More